The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling

por Weinhold, N, Heuck, C, Rosenthal, A, Thanendrarajan, S, Stein, C, Van Rhee, FV, Zangari, M, Hoering, A, Tian, E, Davies, FE, Barlogie, B, Morgan, GJ
Publicado 2015

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of...

por Papanikolaou, X, Rosenthal, A, Dhodapkar, M, Epstein, J, Khan, R, van Rhee, F, Jethava, Y, Waheed, S, Zangari, M, Hoering, A, Crowley, J, Alapat, D, Davies, F, Morgan, G, Barlogie, B
Publicado 2016

Inhibiting MEK in MAPK pathway-activated myeloma

por Heuck, C J, Jethava, Y, Khan, R, van Rhee, F, Zangari, M, Chavan, S, Robbins, K, Miller, S E, Matin, A, Mohan, M, Ali, S M, Stephens, P J, Ross, J S, Miller, V A, Davies, F, Barlogie, B, Morgan, G
Publicado 2016

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

por Papanikolaou, X, Alapat, D, Rosenthal, A, Stein, C, Epstein, J, Owens, R, Yaccoby, S, Johnson, S, Bailey, C, Heuck, C, Tian, E, Joiner, A, van Rhee, F, Khan, R, Zangari, M, Jethava, Y, Waheed, S, Davies, F, Morgan, G, Barlogie, B
Publicado 2015

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

por Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F
Publicado 2016

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

por Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F
Publicado 2016

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

por Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., Buzder, T., Molnar, G., Zangari, M., van Rhee, F., Thanendrarajan, S., Schinke, C., Epstein, J., Davies, F. E., Walker, B. A., Meissner, T., Barlogie, B., Morgan, G. J., Weinhold, N.
Publicado 2017

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

por Rasche, L, Alapat, D, Kumar, M, Gershner, G, McDonald, J, Wardell, C.P, Samant, R, Van Hemert, R, Epstein, J, Williams, A.F, Thanendrarajan, S, Schinke, C, Bauer, M, Ashby, C, Tytarenko, R.G, van Rhee, F, Walker, B.A, Zangari, M, Barlogie, B, Davies, F.E, Morgan, G.J, Weinhold, N
Publicado 2018

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

por Chavan, S S, He, J, Tytarenko, R, Deshpande, S, Patel, P, Bailey, M, Stein, C K, Stephens, O, Weinhold, N, Petty, N, Steward, D, Rasche, L, Bauer, M, Ashby, C, Peterson, E, Ali, S, Ross, J, Miller, V A, Stephens, P, Thanendrarajan, S, Schinke, C, Zangari, M, van Rhee, F, Barlogie, B, Mughal, T I, Davies, F E, Morgan, G J, Walker, B A
Publicado 2017